References

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants

10.1002/cpt.2903 · 2023 · External reference

10.1016/s2215-0366(26)00238-5 · 2026 · Admitted local publication

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

10.1111/j.1365-2710.2006.00763.x · 2006 · External reference

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders

10.1080/15622975.2024.2321553 · 2024 · External reference

Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study

10.1007/s11096-023-01588-8 · 2023 · External reference

The relevance of integrating CYP2C19 phenoconversion effects into clinical pharmacogenetics

10.1055/a-2248-6924 · 2024 · External reference

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

10.4088/jcp.08m04773blu · 2010 · External reference

Effects of pharmacokinetic gene variation on therapeutic drug levels and antidepressant treatment response

10.1055/a-1872-0613 · 2022 · External reference

Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: a pragmatic randomized controlled trial (CYSCE trial)

10.1097/jcp.0000000000001129 · 2019 · External reference

Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review

10.1002/cpt.2754 · 2022 · External reference